Other than FGFR3 fusion-positive BC, we also verified that erdafitinib and quisinostat are synergistic in UM-UC-14 bladder cancer cells with FGFR3 S249C activating mutation, which is one of the most prevalent FGFR3 point mutations in BC. Here, FGFR3 is linked to urinary bladder carcinoma.